Moody Aldrich Partners LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB)

Moody Aldrich Partners LLC acquired a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 83,224 shares of the biotechnology company's stock, valued at approximately $1,547,000. Moody Aldrich Partners LLC owned approximately 0.27% of AnaptysBio as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its holdings in AnaptysBio by 9,778.9% during the 1st quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 1,858 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in AnaptysBio in the 4th quarter worth about $40,000. AlphaQuest LLC increased its stake in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 4,237 shares during the last quarter. Finally, Virtus ETF Advisers LLC increased its stake in AnaptysBio by 24.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after acquiring an additional 936 shares during the last quarter.

AnaptysBio Price Performance

ANAB traded up $0.17 on Friday, hitting $24.05. 212,764 shares of the company were exchanged, compared to its average volume of 641,046. The firm has a fifty day simple moving average of $21.87 and a two-hundred day simple moving average of $18.54. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 282.47% and a negative net margin of 125.70%. The business had revenue of $27.77 million for the quarter, compared to analyst estimates of $15.27 million. As a group, analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has initiated a stock repurchase program on Monday, March 24th that authorizes the company to buyback $75.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to purchase up to 13.1% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.

Insider Transactions at AnaptysBio

In related news, Director Hollings Renton sold 20,925 shares of the firm's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total transaction of $493,202.25. Following the transaction, the director directly owned 4,965 shares in the company, valued at $117,025.05. This trade represents a 80.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 33.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Guggenheim restated a "buy" rating and issued a $90.00 target price (up from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. HC Wainwright upgraded AnaptysBio from a "neutral" rating to a "buy" rating and upped their target price for the stock from $22.00 to $38.00 in a research note on Wednesday, June 4th. Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of AnaptysBio in a research note on Thursday, May 29th. Finally, Johnson Rice restated a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, AnaptysBio has an average rating of "Moderate Buy" and a consensus target price of $42.38.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.